法国全国性调查:马抗胸腺细胞球蛋白(ATGAM)用于获得性再生障碍性贫血患者的报告——代表法国再生障碍性贫血参考中心
该全国性调查分析了2011年9月至2017年3月期间465例接受马抗胸腺细胞球蛋白(ATGAM)联合环孢素(CSA)治疗的再生障碍性贫血患者,其中一线治疗379例(81.5%)。全队列1年部分缓解率72%、完全缓解率13%,严重不良事件主要为感染(24%)、出血(6%)和肝功能异常(5%),12个月时9.7%需二线免疫抑制治疗、15.6%接受移植,55例死亡(主要因感染,53%)。
要点
- ATGAM联合CSA一线治疗379例(81.5%),难治26例、复发33例。
- 全队列1年部分缓解72%、完全缓解13%,重型AA及诊断至IST间隔超过6个月者缓解更差。
- 独立预测更差生存的因素:年龄超过40岁、中性粒细胞低于0.5×10⁹/L、男性、诊断至hATG延迟超过6个月。
核心结论
- 本研究从真实世界角度展示了ATGAM联合CSA的疗效,并确认ATGAM是适合接受HSCT的AA患者的标准免疫抑制治疗。
研究设计与样本
- 法国全国性调查,利用2011年法国健康机构(ANSM)批准的患者名义临时使用(ATU)项目,分析2011年9月至2017年3月期间465例接受ATGAM联合CSA治疗的AA患者。
- 一线治疗379例(81.5%),难治性疾病26例,复发疾病33例。
主要发现
- 全队列1年时72%的患者达部分缓解,13%达完全缓解。
- 重型AA及诊断至IST间隔超过6个月的患者缓解更差。
- 严重不良事件主要与感染(24%)、出血(6%)和肝功能检查升高(5%)相关。
- 12个月时总体9.7%的患者需要二线IST,15.6%接受了移植。
- 研究期间55例患者死亡,主要死于感染(53%)。
临床怎么用
- 作者结论认为ATGAM联合CSA是适合接受HSCT的AA患者的标准免疫抑制治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antithymocyte globulins (ATG) plus cyclosporine (CSA) is the gold standard immunosuppressive treatment (IST) for patients with aplastic anemia. A prospective randomized trial showed in 2011 that hATG was superior to rabbit ATG for first-line treatment of severe AA. The French Health Agency (ANSM) permitted a patient-named authorization for temporary use (ATU) program of hATG (ATGAM, Pfizer) in patients with AA in 2011 since commercial access to hATG is not approved. We took advantage of this program to analyze the outcomes of 465 patients who received antithymocyte globulins (ATGAM) plus CSA as first line treatment (n = 379; 81.5%), or for refractory (n = 26) or relapsed disease (n = 33), from September 2011 to March 2017. In the entire cohort one year, 72% of the patients had partial and 13% had complete response, with worse response for patients with severe AA and a longer interval between diagnosis and IST (more than 6 months). Severe adverse events were mainly linked to infections (24%), hemorrhages (6%), and elevated liver function tests (5%). Overall at 12 months, 9.7% of patients required second line IST and 15.6% received transplantation. Fifty-five patients died during the study mainly because of infections (53%). Factors predicting independently worse survival were age over 40 years, neutrophils less than 0.5 × 109 /L, male gender and longer delay between diagnosis and hATG (>6 months period). This study does illustrate the results of ATGAM with CSA in a true-life perspective and confirms ATGAM as standard of care IST to treat patients with AA not eligible for HSCT.
引用
- Peffault de Latour R, Tabrizi R, Marcais A, et al. Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia. Am J Hematol. 2018. PMID: 29377260. doi:10.1002/ajh.25050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。